new glp 1 drug retatrutide ππ₯ Retatrutide: The Most Powerful Weight-Loss Yet? π§¬π Phase 3 clinical results are turning heads retatrutide, a next-generation triple-agonist targeting GLP-1, GIP and glucagon receptors, is showing unmatched levels of This is the worst the
Description
If you notice symptoms after starting treatment, talk to your doctor to see if your medication could be the cause

Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker

Wykes T, Evans J, Paton C, et al

Abstract Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE
Hjerpsted JB, et al
